Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Medicine is an innovative international pharmaceutical enterprise focusing on the research, development, production and promotion of high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, neurological diseases and other areas, and it is one of the most innovative pharmaceutical leading enterprises in China.

For more than 50 years, Hengrui Medicine has always adhered to the original intention of serving patients, endeavored to guard patients' healthy life and quality of life, and overcome difficulties to promote the high-quality development of the pharmaceutical industry. In the TOP50 list of global pharmaceutical companies published by American Pharmaceutical Manager magazine, Hengrui Medicine has been on the list for 5 consecutive years; in the list of global TOP25 pipeline scale pharmaceutical companies published by Citeline, an internationally renowned consulting organization, Hengrui Medicine has been on the list for 3 consecutive years, and its ranking jumped to No. 8 in 2024, which is again a new record high for Chinese pharmaceutical enterprises; in the "2023 Hurun World 500" released by Hurun Research Institute, Hengrui Medicine ranked 366th; "Best Industrial Enterprises in China's Pharmaceutical R&D Product Lines" released by China Pharmaceutical Industry Information Center in the past years, Hengrui Medicine has topped the list for 11 times.